GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Immunoclin Corp (GREY:IMCL) » Definitions » Debt-to-Revenue

Immunoclin (Immunoclin) Debt-to-Revenue : 0.00 (As of Oct. 2014)


View and export this data going back to 2012. Start your Free Trial

What is Immunoclin Debt-to-Revenue?

Debt-to-Revenue measures a company's ability to pay off its debt.

Immunoclin's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Oct. 2014 was $0.00 Mil. Immunoclin's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Oct. 2014 was $0.00 Mil. Immunoclin's annualized Revenue for the quarter that ended in Oct. 2014 was $0.02 Mil. Immunoclin's annualized Debt-to-Revenue for the quarter that ended in Oct. 2014 was 0.00.


Immunoclin Debt-to-Revenue Historical Data

The historical data trend for Immunoclin's Debt-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Immunoclin Debt-to-Revenue Chart

Immunoclin Annual Data
Trend Feb12 Jan13 Jan14
Debt-to-Revenue
N/A - N/A

Immunoclin Quarterly Data
May11 Aug11 Nov11 Feb12 May12 Aug12 Nov12 Feb13 May13 Aug13 Nov13 Apr14 Jul14 Oct14
Debt-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only N/A N/A N/A N/A -

Competitive Comparison of Immunoclin's Debt-to-Revenue

For the Biotechnology subindustry, Immunoclin's Debt-to-Revenue, along with its competitors' market caps and Debt-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Immunoclin's Debt-to-Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Immunoclin's Debt-to-Revenue distribution charts can be found below:

* The bar in red indicates where Immunoclin's Debt-to-Revenue falls into.



Immunoclin Debt-to-Revenue Calculation

Debt-to-Revenue measures a company's ability to pay off its debt.

Immunoclin's Debt-to-Revenue for the fiscal year that ended in Jan. 2014 is calculated as

Immunoclin's annualized Debt-to-Revenue for the quarter that ended in Oct. 2014 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-Revenue, the Revenue of the last fiscal year is used. In calculating the annualized quarterly data, the Revenue data used here is four times the quarterly (Oct. 2014) Revenue data.


Immunoclin Debt-to-Revenue Related Terms

Thank you for viewing the detailed overview of Immunoclin's Debt-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Immunoclin (Immunoclin) Business Description

Traded in Other Exchanges
N/A
Address
9107 Wilshire Boulevard, Suite 450, Beverly Hills, CA, USA, 90210
Immunoclin Corp is engaged in immunology research and development skill to serve the pharmaceutical, biotechnology and food industries, providing comprehensive, clinical and basic science research expertise at a commercial scale and quality.

Immunoclin (Immunoclin) Headlines

No Headlines